Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials.
Maggio A, Filosa A, Vitrano A, Aloj G, Kattamis A, Ceci A, Fucharoen S, Cianciulli P, Grady RW, Prossomariti L, Porter JB, Iacono A, Cappellini MD, Bonifazi F, Cassarà F, Harmatz P, Wood J, Gluud C. Maggio A, et al. Among authors: cianciulli p. Blood Cells Mol Dis. 2011 Oct 15;47(3):166-75. doi: 10.1016/j.bcmd.2011.07.002. Epub 2011 Aug 16. Blood Cells Mol Dis. 2011. PMID: 21843958 Review.
Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial.
Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, Di Gregorio F, Garozzo G, Malizia R, Magnano C, Mangiagli A, Quarta G, Rizzo M, D'Ascola DG, Rizzo A, Midiri M. Maggio A, et al. Among authors: cianciulli p. Blood Cells Mol Dis. 2002 Mar-Apr;28(2):196-208. doi: 10.1006/bcmd.2002.0510. Blood Cells Mol Dis. 2002. PMID: 12064916 Clinical Trial.
Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Magnano C, Rizzo M, Caruso V, Gerardi C, Argento C, Campisi S, Cantella F, Commendatore F, D'Ascola DG, Fidone C, Ciancio A, Galati MC, Giuffrida G, Cingari R, Giugno G, Lombardo T, Prossomariti L, Malizia R, Meo A, Roccamo G, Romeo MA, Violi P, Cianciulli P, Rigano P. Maggio A, et al. Among authors: cianciulli p. Blood Cells Mol Dis. 2009 May-Jun;42(3):247-51. doi: 10.1016/j.bcmd.2009.01.002. Epub 2009 Feb 23. Blood Cells Mol Dis. 2009. PMID: 19233692 Clinical Trial.
Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial.
Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Romeo MA, Magnano C, Caruso V, Argento C, Gerardi C, Campisi S, Violi P, Malizia R, Cianciulli P, Rizzo M, D'Ascola DG, Quota A, Prossomariti L, Fidone C, Rigano P, Pepe A, D'Amico G, Morabito A, Gluud C. Maggio A, et al. Among authors: cianciulli p. Br J Haematol. 2009 Apr;145(2):245-54. doi: 10.1111/j.1365-2141.2009.07609.x. Epub 2009 Feb 19. Br J Haematol. 2009. PMID: 19236376 Free article. Clinical Trial.
Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
Lai ME, Grady RW, Vacquer S, Pepe A, Carta MP, Bina P, Sau F, Cianciulli P, Maggio A, Galanello R, Farci P. Lai ME, et al. Among authors: cianciulli p. Blood Cells Mol Dis. 2010 Aug 15;45(2):136-9. doi: 10.1016/j.bcmd.2010.05.005. Epub 2010 Jun 17. Blood Cells Mol Dis. 2010. PMID: 20678715
Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
Pantalone GR, Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Romeo MA, Magnano C, Caruso V, Argento C, Gerardi C, Campisi S, Violi P, Malizia R, Cianciulli P, Rizzo M, D'Ascola DG, Quota A, Prossomariti L, Fidone C, Rigano P, Pepe A, D'Amico G, Morabito A, Gluud C. Pantalone GR, et al. Among authors: cianciulli p. Hemoglobin. 2011;35(3):206-16. doi: 10.3109/03630269.2011.570674. Hemoglobin. 2011. PMID: 21599433 Clinical Trial.
Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients.
Maggio A, Vitrano A, Lucania G, Capra M, Cuccia L, Gagliardotto F, Pitrolo L, Prossomariti L, Filosa A, Caruso V, Gerardi C, Campisi S, Cianciulli P, Rizzo M, D'Ascola G, Ciancio A, Di Maggio R, Calvaruso G, Pantalone GR, Rigano P. Maggio A, et al. Among authors: cianciulli p. Am J Hematol. 2012 Jul;87(7):732-3. doi: 10.1002/ajh.23219. Epub 2012 May 24. Am J Hematol. 2012. PMID: 22622672 Free article. Clinical Trial.
Serial echocardiographic left ventricular ejection fraction measurements: a tool for detecting thalassemia major patients at risk of cardiac death.
Maggio A, Vitrano A, Calvaruso G, Barone R, Rigano P, Mancuso L, Cuccia L, Capra M, Pitrolo L, Prossomariti L, Filosa A, Caruso V, Gerardi C, Campisi S, Cianciulli P, Elefteriou A, Angastiniotis M, Hamza H, Telfer P, Walker JM, Phrommintikul A, Chattipakorn N. Maggio A, et al. Among authors: cianciulli p. Blood Cells Mol Dis. 2013 Apr;50(4):241-6. doi: 10.1016/j.bcmd.2012.12.002. Epub 2013 Jan 20. Blood Cells Mol Dis. 2013. PMID: 23337255
Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major.
Filosa A, Vitrano A, Rigano P, Calvaruso G, Barone R, Capra M, Cuccia L, Gagliardotto F, Pitrolo L, Prossomariti L, Casale M, Caruso V, Gerardi C, Campisi S, Cianciulli P, Rizzo M, D'Ascola G, Ciancio A, Maggio A. Filosa A, et al. Among authors: cianciulli p. Blood Cells Mol Dis. 2013 Aug;51(2):85-8. doi: 10.1016/j.bcmd.2013.04.002. Epub 2013 Apr 28. Blood Cells Mol Dis. 2013. PMID: 23628348
83 results